Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Cost of Patients With Hemophilia A and High-Titer Inhibitors in Colombia.

Sánchez-Vanegas G, Linares A, Sarmiento I, Solano MH, Romano G, Castro C.

Value Health Reg Issues. 2019 Dec;20:164-171. doi: 10.1016/j.vhri.2019.08.473. Epub 2019 Oct 8.

PMID:
31604188
2.

Community factors associated with stunting, overweight and food insecurity: a community-based mixed-method study in four Andean indigenous communities in Ecuador.

Walrod J, Seccareccia E, Sarmiento I, Pimentel JP, Misra S, Morales J, Doucet A, Andersson N.

BMJ Open. 2018 Jul 6;8(7):e020760. doi: 10.1136/bmjopen-2017-020760.

3.

Safe Birth and Cultural Safety in southern Mexico: study protocol for a randomised controlled trial.

Sarmiento I, Paredes-Solís S, Andersson N, Cockcroft A.

Trials. 2018 Jul 4;19(1):354. doi: 10.1186/s13063-018-2712-6.

4.
5.

In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene.

Arhin FF, Sarmiento I, Moeck G.

Int J Antimicrob Agents. 2014 Jul;44(1):65-8. doi: 10.1016/j.ijantimicag.2014.03.015. Epub 2014 May 23.

PMID:
24906505
6.

[Correlation of the t(9;22), t(12;21), and DNA hyperdiploid content with immunophenotype and proliferative rate of leukemic B-cells of pediatric patients with B-cell acute lymphoblastic leukemia].

Quijano SM, Torres MM, Vásquez LE, Cuéllar GE, Romero ML, Martín EL, Linares A, Castaño S, Sarmiento IC, Cabrera E, Uribe GI, Andrade RE, Saavedra CE.

Biomedica. 2013 Jul-Sep;33(3):468-86. Spanish.

PMID:
24652183
7.

Oritavancin retains bactericidal activity in vitro against standard and high inocula of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA).

Arhin FF, Sarmiento I, Moeck G.

Int J Antimicrob Agents. 2013 Apr;41(4):397-8. doi: 10.1016/j.ijantimicag.2012.12.004. Epub 2013 Jan 29. No abstract available.

PMID:
23374976
8.

Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.

Belley A, Arhin FF, Sarmiento I, Deng H, Rose W, Moeck G.

Antimicrob Agents Chemother. 2013 Jan;57(1):205-11. doi: 10.1128/AAC.01428-12. Epub 2012 Oct 22.

9.

An adjunct exercise program for serious mental illness: who chooses to participate and is it feasible?

Sylvia LG, Kopeski L, Brown C, Bolton P, Laudate C, DiGangi G, Martin P, Reid JA, Martowski JC, Meade A, Sarmiento IA, Wang J, Utschig AC, Siegel A, Neuhaus EC.

Community Ment Health J. 2013 Apr;49(2):213-9. doi: 10.1007/s10597-012-9555-5. Epub 2012 Oct 13.

PMID:
23064968
10.

Activity of oritavancin and comparators in vitro against standard and high inocula of Staphylococcus aureus.

Arhin FF, Sarmiento I, Parr TR Jr, Moeck G.

Int J Antimicrob Agents. 2012 Feb;39(2):159-62. doi: 10.1016/j.ijantimicag.2011.09.017. Epub 2011 Nov 8.

PMID:
22070858
11.

Rape stereotypes and labeling: awareness of victimization and trauma.

Sarmiento I.

Psychol Rep. 2011 Feb;108(1):141-8.

PMID:
21526600
12.

Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.

Belley A, McKay GA, Arhin FF, Sarmiento I, Beaulieu S, Fadhil I, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2010 Dec;54(12):5369-71. doi: 10.1128/AAC.00760-10. Epub 2010 Sep 27.

13.

Assessment of oritavancin serum protein binding across species.

Arhin FF, Belley A, McKay G, Beaulieu S, Sarmiento I, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2010 Aug;54(8):3481-3. doi: 10.1128/AAC.00271-10. Epub 2010 May 24.

14.

Synthesis and in vitro evaluation of bisphosphonated glycopeptide prodrugs for the treatment of osteomyelitis.

Tanaka KS, Dietrich E, Ciblat S, Métayer C, Arhin FF, Sarmiento I, Moeck G, Parr TR Jr, Far AR.

Bioorg Med Chem Lett. 2010 Feb 15;20(4):1355-9. doi: 10.1016/j.bmcl.2010.01.006. Epub 2010 Jan 11.

PMID:
20097069
15.

Time-kill kinetics of oritavancin and comparator agents against Streptococcus pyogenes.

Arhin FF, McKay GA, Beaulieu S, Sarmiento I, Parr TR Jr, Moeck G.

Int J Antimicrob Agents. 2009 Dec;34(6):550-4. doi: 10.1016/j.ijantimicag.2009.08.012. Epub 2009 Oct 8.

PMID:
19818587
16.

Family functioning and depression in low-income Latino couples.

Sarmiento IA, Cardemil EV.

J Marital Fam Ther. 2009 Oct;35(4):432-45. doi: 10.1111/j.1752-0606.2009.00139.x.

PMID:
19785700
17.

Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus.

Arhin FF, McKay GA, Beaulieu S, Sarmiento I, Parr TR Jr, Moeck G.

Diagn Microbiol Infect Dis. 2009 Oct;65(2):207-10. doi: 10.1016/j.diagmicrobio.2009.05.022.

PMID:
19748436
18.

Comparative in vitro activity of oritavancin against recent, genetically diverse, community-associated meticillin-resistant Staphylococcus aureus (MRSA) isolates.

Arhin FF, Kurepina N, Sarmiento I, Parr TR Jr, Moeck G, Kreiswirth B.

Int J Antimicrob Agents. 2010 Jan;35(1):93-4. doi: 10.1016/j.ijantimicag.2009.07.012. Epub 2009 Sep 9. No abstract available.

PMID:
19744836
19.

Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin.

Arhin FF, Sarmiento I, Parr TR Jr, Moeck G.

J Antimicrob Chemother. 2009 Oct;64(4):868-70. doi: 10.1093/jac/dkp286. Epub 2009 Aug 4. No abstract available.

PMID:
19656783
20.

Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.

McKay GA, Beaulieu S, Arhin FF, Belley A, Sarmiento I, Parr T Jr, Moeck G.

J Antimicrob Chemother. 2009 Jun;63(6):1191-9. doi: 10.1093/jac/dkp126. Epub 2009 Apr 15.

PMID:
19369269
21.

Impact of human serum albumin on oritavancin in vitro activity against enterococci.

McKay GA, Beaulieu S, Sarmiento I, Arhin FF, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2009 Jun;53(6):2687-9. doi: 10.1128/AAC.00197-09. Epub 2009 Apr 6.

22.

[Chronic disease impact on partners. An explorative study].

Pacini G, Sarmiento I.

G Ital Med Lav Ergon. 2008 Jul-Sep;30(3 Suppl B):B54-61. Italian.

PMID:
19288778
23.

Bisphosphonated benzoxazinorifamycin prodrugs for the prevention and treatment of osteomyelitis.

Reddy R, Dietrich E, Lafontaine Y, Houghton TJ, Belanger O, Dubois A, Arhin FF, Sarmiento I, Fadhil I, Laquerre K, Ostiguy V, Lehoux D, Moeck G, Parr TR Jr, Rafai Far A.

ChemMedChem. 2008 Dec;3(12):1863-8. doi: 10.1002/cmdc.200800255. No abstract available.

PMID:
18973169
24.

Linking bisphosphonates to the free amino groups in fluoroquinolones: preparation of osteotropic prodrugs for the prevention of osteomyelitis.

Houghton TJ, Tanaka KS, Kang T, Dietrich E, Lafontaine Y, Delorme D, Ferreira SS, Viens F, Arhin FF, Sarmiento I, Lehoux D, Fadhil I, Laquerre K, Liu J, Ostiguy V, Poirier H, Moeck G, Parr TR Jr, Far AR.

J Med Chem. 2008 Nov 13;51(21):6955-69. doi: 10.1021/jm801007z. Epub 2008 Oct 4.

PMID:
18834106
25.

Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis.

Tanaka KS, Houghton TJ, Kang T, Dietrich E, Delorme D, Ferreira SS, Caron L, Viens F, Arhin FF, Sarmiento I, Lehoux D, Fadhil I, Laquerre K, Liu J, Ostiguy V, Poirier H, Moeck G, Parr TR Jr, Rafai Far A.

Bioorg Med Chem. 2008 Oct 15;16(20):9217-29. doi: 10.1016/j.bmc.2008.09.010. Epub 2008 Sep 9.

PMID:
18815051
26.

Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.

Arhin FF, Sarmiento I, Belley A, McKay GA, Draghi DC, Grover P, Sahm DF, Parr TR Jr, Moeck G.

Antimicrob Agents Chemother. 2008 May;52(5):1597-603. doi: 10.1128/AAC.01513-07. Epub 2008 Feb 25.

27.

Genetics and congenital malformations: interpretations, attitudes and practices in suburban communities and the shamans of ecuador.

Paz-Y-Miño C, Sánchez ME, Sarmiento I, Leone PE.

Community Genet. 2006;9(4):268-73.

PMID:
17003537
29.

Triaminotriazine DNA helicase inhibitors with antibacterial activity.

McKay GA, Reddy R, Arhin F, Belley A, Lehoux D, Moeck G, Sarmiento I, Parr TR, Gros P, Pelletier J, Far AR.

Bioorg Med Chem Lett. 2006 Mar 1;16(5):1286-90. Epub 2005 Dec 15.

PMID:
16343901
30.

Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humans.

Gören JL, Stoll AL, Damico KE, Sarmiento IA, Cohen BM.

Pharmacotherapy. 2004 Nov;24(11):1501-7.

PMID:
15537554

Supplemental Content

Loading ...
Support Center